Frankfurt
26.02.25
08:10 Uhr
0,144 Euro
+0,002
+1,70 %
+1,70 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,171 | 0,171 | 14:20 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.02. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 193 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 27.01. | Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio for Precision Surgery in Head and Neck Cancers | 235 | Business Wire | Cellvizio was successfully integrated into TransOral Robotic Surgery (TORS) procedures to assess peripheral mucosal margins in the larynx, oropharynx and hypopharynx Cellvizio helped identify... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 21.01. | Mauna Kea Technologies: Half-Year Liquidity Contract Statement for H2 2024 With the Brokerage Firm Gilbert Dupont | 594 | Business Wire | Regulatory News:
Under the liquidity contract between the company MAUNA KEA TECHNOLOGIES (Paris:ALMKT) and the brokerage firm Gilbert Dupont, the following resources appeared on the liquidity account... ► Artikel lesen | |
| 20.01. | Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex | 257 | Business Wire | 13th U.S. AI patent awarded to Mauna Kea Expanded patent portfolio boosts platform value, supports strategic partnerships
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT)... ► Artikel lesen | |
| 15.01. | Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update | 298 | Business Wire | Full Year Sales excluding licenses of €5.6m, down 9% YoY amid delayed capital sales and no revenue from JV in China Two specialized investment banks RM Global and Bucephale Finance mandated to... ► Artikel lesen | |
| 14.01. | Mauna Kea Technologies Announces Its 2025 Financial Calendar | 206 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®,the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces... ► Artikel lesen | |
| 09.01. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 336 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 04.12.24 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 298 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 26.11.24 | Mauna Kea Technologies: Raising Pancreatic Cancer Awareness Through Patient Voices | 121 | Business Wire | With its Needle-Based Confocal Laser Endomicroscopy Solution, Mauna Kea is Playing a Decisive Role in the Fight Against Pancreatic Cancer
Regulatory News:
This Pancreatic Cancer Awareness Month... ► Artikel lesen | |
| 20.11.24 | Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador | 103 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is pleased... ► Artikel lesen | |
| 13.11.24 | Mauna Kea Technologies Provides an Update on Its Recent Developments | 325 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, provides... ► Artikel lesen | |
| 06.11.24 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 291 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website:... ► Artikel lesen | |
| 17.10.24 | Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance | 396 | Business Wire | Major New Study Presented at the World's Largest Gastroenterology Congress Validation of Mauna Kea's Growth Strategy with CellTolerance® in a $6 Billion a Year Market Opportunity
Regulatory... ► Artikel lesen | |
| 15.10.24 | Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales | 386 | Business Wire | Confirmation of lower breakeven point trajectory with 9% Reduction in Operational Expenses Q3 2024 Sales Growth of +24%1 Driven by New System Sales in the U.S. and Europe Official Launch of... ► Artikel lesen | |
| 04.10.24 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 446 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 01.10.24 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 266 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 16.09.24 | Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio | 261 | Business Wire | Recent clinical study published in Journal of Thoracic Disease supports the combination of Cellvizio with Electromagnetic Navigation Bronchoscopy to improve diagnosis and treatment of lung cancer... ► Artikel lesen | |
| 10.09.24 | Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio | 385 | Business Wire | Formal letter requests coverage of Cellvizio and its dedicated category I CPT Codes to significantly enhance early detection of Barrett's Esophagus and Esophageal Cancer Prevalence of Esophageal... ► Artikel lesen | |
| 09.08.24 | Mauna Kea Technologies: Monthly information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 490 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 25.07.24 | Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024 | 527 | Business Wire | Q2 2024 Sales Up 48% vs. Q1 but Down 20% Year-on-Year1 as U.S. Systems Sales Scheduled for the Second Half of 2024 and Temporary Reimbursement Reduction Impacting PPU Revenue U.S. PPU Volume... ► Artikel lesen |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,130 | -1,37 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 13.02.2025 | Das Instrument PSH0 CA81752F1062 SERNOVA BIOTHERAPEUTICS EQUITY hat seinen ersten Handelstag am 13.02.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG NAM0, SettlCurr EUR, CCP Y
The instrument PSH0 CA81752F1062... ► Artikel lesen | |
| FAMICORD | 4,180 | 0,00 % | Vita 34 firmiert um: Neuer Name FamiCord AG | Die Vita 34 AG firmiert ab sofort unter dem Namen FamiCord AG. Der neue Name basiert auf der bekanntesten Konzernmarke und soll die Expansion des Leipziger Unternehmens in weitere Geschäftsfelder unterstützen.... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,720 | +3,91 % | Geratherm Medical Aktie: Fortschritte führen zum Erfolg! | Die Geratherm Medical AG, ein Spezialist für medizinische Temperaturmesstechnik, verzeichnet einen vielversprechenden Jahresbeginn 2025. Der Aktienkurs des Unternehmens stieg am 17. Januar auf 3,68... ► Artikel lesen | |
| PLUS THERAPEUTICS | 1,164 | +6,99 % | XFRA DIVERSE INSTRUMENTE: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCASTOR MARITIME... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,712 | -2,73 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
| MEDICLIN | 2,880 | -0,69 % | Mediclin erhöht Prognose - Aktie stark im Plus | Die Mediclin AG hat am Dienstag ihre Prognose für das Geschäftsjahr 2024 angehoben. Das erwartete Konzern-EBIT wurde auf eine Spanne von 48,0 bis 54,0 Millionen Euro erhöht, nachdem zuvor 33,0 bis 39... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,520 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando | BOULDER, CO / ACCESS Newswire / February 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc. - 10-Q, Quarterly Report | ||
| VERU | 0,493 | -2,95 % | Veru Inc. Direktor Michael Rankowitz erwirbt Stammaktien im Wert von 84.350 US-Dollar | ||
| LIFEWARD | 1,605 | 0,00 % | Lifeward Ltd.: Lifeward Announces CEO Transition | CEO Larry Jasinski to Retire Company Begins Search for New Leader to Drive Next Phase of Growth Company Provides Preliminary Full-Year 2024 Revenue Reschedules Virtual Investor Event Until Later... ► Artikel lesen | |
| LIGHT AI | 0,462 | 0,00 % | Light AI Inc: Light AI enters partnership with Eliquent | ||
| FRESENIUS | 39,440 | +7,88 % | EQS-PVR: Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
19.02.2025 /... ► Artikel lesen | |
| GERRESHEIMER | 79,95 | -0,31 % | EQS-AFR: Gerresheimer AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Gerresheimer AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Gerresheimer AG: Vorabbekanntmachung über... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 54,60 | +0,70 % | Dividendenbekanntmachungen (19.02.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 2020 BULKERS LTD BMG9156K1018 0,03 USD 0,0287 EUR AFLAC INC US0010551028 0,58 USD 0,555 EUR BLUE OWL CAPITAL INC US09581B1035 0... ► Artikel lesen |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +1,70 % bei einem Aktienkurs von 0,144 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.
